With a shared purpose, we can realize the true promise of CRISPR and improve healthcare, providing hope to more patients with ...

Researchers reprogrammed bacterial bridge recombinases to edit large genomic regions in mammalian cells, revealing a ...

Wave is expecting feedback from US regulators on a path forward for WVE-006 as a potential alpha-1 antitrypsin deficiency therapy in mid-2026.

Gene therapy holds the promise of preventing and curing disease by manipulating gene expression within a patient's cells. However, to be effective, the new gene must make it into a cell's nucleus. The ...

A research team has successfully demonstrated the world's first gene-editing treatment for Leber's hereditary optic ...

By simplifying the engineering process and expanding what can be built, the Golden Gate method greatly broadens the possibilities for scientists working to develop bacteriophages as tools to combat ...

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the first public showcase of QIAsprint Connect at SLAS 2026 in Boston, marking QIAGEN’s entry into high-throughput benchtop ...

Shoutout to GoDaddy for sponsoring today's video! Check out to venture into the Digital Wasteland and find out what business ...

Civitai—an online marketplace for buying and selling AI-generated content, backed by the venture capital firm Andreessen Horowitz—is letting users buy custom instruction files for generating celebrity ...

Market OverviewThe global cell and gene therapy market is undergoing rapid and transformative growth, reflecting its increasing importance in modern healthcare.The market is projected to expand at a ...

Shoutout to GoDaddy for sponsoring today's video! Check out to venture into the Digital Wasteland and find out what business ...

Few companies stand better poised than Beam Therapeutics to reap the first fruits of the FDA’s promised flexibility toward cell and gene therapies. | Riding a regulatory win for its base editing ...